Developing a test to measure Alzheimer’s disease markers in cerebrospinal fluid
Official title: Multiplexed immunoassay for building patient-specific molecular profiles of CSF amyloid beta and TAU
Funded at Adeptrix Corporation · NIH-10707200 · Data updated 2026-11-12
This study is working on a new test that looks at the fluid around your brain and spine to find certain proteins linked to Alzheimer's disease, which could help doctors diagnose it better and personalize treatments just for you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Adeptrix Corporation NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 30, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,433,652 |
| NIH project number | 5R44AG080889-02 |
| Project ID | NIH-10707200 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
✕Less likely to help
Patients with other types of dementia not related to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on creating a specialized test that can analyze cerebrospinal fluid (CSF) to identify specific protein markers associated with Alzheimer's disease, namely amyloid beta and TAU. By using advanced techniques to capture and measure these proteins, the study aims to build detailed molecular profiles for individual patients. This could help in diagnosing Alzheimer's disease more accurately and tailoring treatments based on a patient's unique biomarker profile. The approach utilizes innovative technology to enhance the detection of these proteins, which are crucial for understanding the disease's progression.
Why it matters
Potential benefit: If successful, this research could lead to more precise diagnostics and personalized treatment strategies for patients with Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in using similar biomarker profiling approaches for Alzheimer's disease, indicating potential for success in this novel application.
Where this research is happening
-
Adeptrix Corporation
Boston, United States Active
Researchers
- Principal investigator: Bergo, Vladislav — Adeptrix Corporation
- Study coordinator: Bergo, Vladislav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.